Cargando…

Titration of signalling output: insights into clinical combinations of MEK and AKT inhibitors

BACKGROUND: We aimed to understand the relative contributions of inhibiting MEK and AKT on cell growth to guide combinations of these agents. MATERIALS AND METHODS: A panel of 20 cell lines was exposed to either the MEK inhibitor, PD0325901, or AKT inhibitor, AKT 1/2 inhibitor. p-ERK and p-S6 ELISAs...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stewart, A., Thavasu, P., de Bono, J. S., Banerji, U.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2015
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4478974/ https://www.ncbi.nlm.nih.gov/pubmed/25908604 http://dx.doi.org/10.1093/annonc/mdv188

Ejemplares similares

Insights into significance of combined inhibition of MEK and m-TOR signalling output in KRAS mutant non-small-cell lung cancer
por: Broutin, Sophie, et al.
Publicado: (2016)

Discovery of Novel AKT Inhibitors with Enhanced Anti-Tumor Effects in Combination with the MEK Inhibitor
por: Dumble, Melissa, et al.
Publicado: (2014)

Oncogenic PI3K/AKT promotes the step-wise evolution of combination BRAF/MEK inhibitor resistance in melanoma
por: Irvine, Mal, et al.
Publicado: (2018)

Evaluation of the combination of the dual m-TORC1/2 inhibitor vistusertib (AZD2014) and paclitaxel in ovarian cancer models
por: Wong Te Fong, Anne-Christine, et al.
Publicado: (2017)

Combined AKT and MEK Pathway Blockade in Pre-Clinical Models of Enzalutamide-Resistant Prostate Cancer
por: Toren, Paul, et al.
Publicado: (2016)

A PC-based titrator for flow gradient titrations
por: Fuhrmann, B., et al.
Publicado: (1993)

Complications of hyperglycaemia with PI3K–AKT–mTOR inhibitors in patients with advanced solid tumours on Phase I clinical trials
por: Geuna, E, et al.
Publicado: (2015)

Left ventricular output indices and sacubitril/valsartan titration: role of stroke volume index
por: Tolomeo, Paolo, et al.
Publicado: (2022)

Integrating BRAF/MEK inhibitors into combination therapy for melanoma
por: Smalley, K S M, et al.
Publicado: (2009)

A study of PD-L1 expression in KRAS mutant non-small cell lung cancer cell lines exposed to relevant targeted treatments
por: Minchom, Anna, et al.
Publicado: (2017)

Overactivation of Akt Contributes to MEK Inhibitor Primary and Acquired Resistance in Colorectal Cancer Cells
por: Tsubaki, Masanobu, et al.
Publicado: (2019)

Vertical Targeting of AKT and mTOR as Well as Dual Targeting of AKT and MEK Signaling Is Synergistic in Hepatocellular Carcinoma
por: Ewald, Florian, et al.
Publicado: (2015)

Automated titrations: the use of automated multiple flow injection analysis for the titration of discrete samples
por: Stewart, Kent K., et al.
Publicado: (1981)

Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma
por: Atefi, Mohammad, et al.
Publicado: (2015)

Risk factors for MEK-associated retinopathy in patients with advanced melanoma treated with combination BRAF and MEK inhibitor therapy
por: Booth, Andrew E. C., et al.
Publicado: (2020)

MEK Inhibitor U0126 Reverses Protection of Axons from Wallerian Degeneration Independently of MEK–ERK Signaling
por: Evans, Catherine, et al.
Publicado: (2013)

MEK and PI3K-AKT inhibitors synergistically block activated IL7 receptor signaling in T-cell acute lymphoblastic leukemia
por: Canté-Barrett, K, et al.
Publicado: (2016)

Association of creatine kinase and skin toxicity in phase I trials of anticancer agents
por: Moreno Garcia, V, et al.
Publicado: (2012)

MEK inhibitors and their potential in the treatment of advanced melanoma: the advantages of combination therapy
por: Tran, Khiem A, et al.
Publicado: (2015)

Safety of BRAF+MEK Inhibitor Combinations: Severe Adverse Event Evaluation
por: Meirson, Tomer, et al.
Publicado: (2020)

Combination MEK and mTOR inhibitor therapy is active in models of glioblastoma
por: Schreck, Karisa C, et al.
Publicado: (2020)

Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management
por: Heinzerling, Lucie, et al.
Publicado: (2019)

Combining HDAC and MEK Inhibitors with Radiation against Glioblastoma-Derived Spheres
por: Essien, Eno I., et al.
Publicado: (2022)

Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway
por: Atefi, Mohammad, et al.
Publicado: (2011)

Blockage of the mevalonate pathway overcomes the apoptotic resistance to MEK inhibitors with suppressing the activation of Akt in cancer cells
por: Iizuka-Ohashi, Mahiro, et al.
Publicado: (2018)

Regulation of MEK inhibitor selumetinib sensitivity by AKT phosphorylation in the novel BRAF L525R mutant
por: Nakai, Chikako, et al.
Publicado: (2023)

HER3 expression and MEK activation in non-small-cell lung carcinoma
por: Manickavasagar, Thubeena, et al.
Publicado: (2021)

Direct binding of MEK1 and MEK2 to AKT induces Foxo1 phosphorylation, cellular migration and metastasis
por: Procaccia, Shiri, et al.
Publicado: (2017)

Lessons from clinical trials on triple combination of immune checkpoint inhibitors and BRAF/MEK inhibitors in BRAF-mutant melanoma
por: Maeda, Takuya, et al.
Publicado: (2023)

HDAC Inhibitor Titration of Transcription and Axolotl Tail Regeneration
por: Voss, S. Randal, et al.
Publicado: (2021)

Rapid measurement of inhibitor binding kinetics by isothermal titration calorimetry
por: Di Trani, Justin M., et al.
Publicado: (2018)

Combination therapy for melanoma with BRAF/MEK inhibitor and immune checkpoint inhibitor: a mathematical model
por: Lai, Xiulan, et al.
Publicado: (2017)

Combination Treatment with MEK and AKT Inhibitors Is More Effective than Each Drug Alone in Human Non-Small Cell Lung Cancer In Vitro and In Vivo
por: Meng, Jieru, et al.
Publicado: (2010)

An increased cell cycle gene network determines MEK and Akt inhibitor double resistance in triple-negative breast cancer
por: van der Noord, Vera E., et al.
Publicado: (2019)

Costunolide is a dual inhibitor of MEK1 and AKT1/2 that overcomes osimertinib resistance in lung cancer
por: Tian, Xueli, et al.
Publicado: (2022)

SODD Promotes Lung Cancer Tumorigenesis by Activating the PDK1/AKT and RAF/MEK/ERK Signaling
por: Bao, Fan, et al.
Publicado: (2023)

Intracranial Control With Combination BRAF and MEK Inhibitor Therapy in Patients With Metastatic Melanoma
por: Hui, Caressa, et al.
Publicado: (2022)

Serous Retinopathy Associated With Combination MEK and Fibroblast Growth Factor Receptor Inhibitor
por: Day, H. Russell, et al.
Publicado: (2023)

MEK and the inhibitors: from bench to bedside
por: Akinleye, Akintunde, et al.
Publicado: (2013)

Current Development Status of MEK Inhibitors
por: Cheng, Ying, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ufc7cs78gd73sqnkuq311lpjei